PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH.

It acts on melanocortin receptors in the central nervous system, addressing desire rather than vascular response.

Considered where desire, not erectile function, is the presenting concern — and after cardiovascular and hormonal causes have been assessed.

• You are an established MECCA patient, or are willing to begin with a consultation.
• You have a clearly defined goal that this therapy plausibly addresses.
• Your recent laboratory work and history have been reviewed by your clinician.
• You are able to attend the monitoring intervals the protocol requires.

• You are pregnant, breastfeeding, or planning pregnancy.
• You have an active malignancy or an unresolved undiagnosed symptom.
• You take a medication that interacts with this therapy.
• Your goal is better served by training, nutrition, sleep or an existing prescription.

• Current medications, supplements and prescriptions written elsewhere.
• Relevant baseline testing, and whether an interval draw is needed first.
• Monitoring cadence, expected review date and the criteria for stopping.
• Whether a non-pharmacologic route addresses the same goal first.

• Prescription-only. Never self-source or self-administer outside a supervised plan.
• Injection-site reactions, bruising and transient discomfort are the most commonly reported effects.
• Report any new or unexpected symptom to your care team before the next scheduled dose.